CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...